SAN DIEGO, CA — January 7, 2026 — Leads & Copy — DexCom, Inc. (Nasdaq:DXCM) has begun a new era of innovation under the leadership of President and CEO Jake Leach, who assumed his expanded responsibilities on Jan. 1.
Leach’s tenure begins with appearances at CES 2026 on Jan. 7, where he will join a mainstage panel alongside leaders from Dexcom partners ŌURA and Rimidi. Subsequently, Leach will deliver the opening presentation at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12 at 7:30 A.M. PT, where he will present his vision for Dexcom and outline key milestones to expect in 2026.
During these upcoming events, Leach will share updates taking place across Dexcom’s product portfolio while the company maintains a steady commitment to users with diabetes and beyond. These updates include:
A completely reimagined app experience for Stelo: With investments in AI-enabled features to personalize insights and the user experience, including more robust capabilities around food logging like macronutrient information, Dexcom is revamping the Stelo app to continue making accurate glucose health information more consumer-friendly.
Increased product availability to better serve the diabetes community: Following the initial launch of the Dexcom G7 15 Day CGM System to durable medical equipment (DME) providers, the longest lasting CGM system*,†,1 with 15.5 days of wear* began shipping to pharmacies in early January 2026.
Expanded coverage for glucose biosensing technology for people with diabetes: Dexcom added coverage for several million people globally over the past 2 years1 and remains committed to achieving even greater coverage to increase access to glucose biosensors for anyone with diabetes.
More personalized user experiences: 2026 will be another year of innovation from Dexcom, coming off the many product updates introduced in 2025, including the Dexcom G7 integration with Insulet’s Omnipod® 5 app on iOS systems in the US, the Stelo integration with Oura Ring, the Dexcom G7 integration with NovoPen® 6 and NovoPen Echo® Plus, AI-powered Smart Food Logging and more.
Always On: How Continuous Health Data is Transforming Care at CES 2026 on Jan. 7 at 10 A.M. PT is open to all registered CES attendees and will also be live-streamed. Dexcom’s J.P. Morgan presentation will be available at investors.dexcom.com on Monday, Jan. 12.
Leach assumes the role of CEO from Kevin Sayer, who spent the last decade guiding Dexcom through growth. Under Sayer’s leadership, Dexcom grew from approximately $250 million to more than $4.6 billion in annual revenue and pioneered the CGM category with a long list of industry firsts, including the first approval to replace fingersticks in treatment decisions, the first approval to send glucose data directly to smartphones and the first CGM cleared for use in the US without a prescription.
Dexcom empowers people to take control of health through biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
*A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. In other words, when using the product per the package labeling, approximately 26% of sensors may not last for the full 15 days.
†Excludes implantable CGM systems.
1 Dexcom, Data on File, 2025
Source: Dexcom
